Updates in Hematopoietic Stem Cell Transplantation: A Treatment Option for Hematological Malignancies
November 2, 2012
This one-day conference aims to provide a comprehensive overview of updates in the use of hematopoietic stem cell transplantation for treatment of hematological malignancies.
Target Audience:
Hematologists, oncologists, and other health care professionals working with individuals impacted by hematological malignancies.
Course Objectives:
Upon completion of this conference the participant should be able to:
- Integrate new evidence into everyday clinical practice, which will help improve quality of care being delivered to patients with hematological malignancies.
- Implement practice changes in stem cell transplant as a treatment option for hematological malignancies, including acute leukemia, myelodysplastic syndrome, myeloma, and lymphoma, as well as utilization of supportive care options for infectious complications.
- Stimulate awareness of new clinical strategies, including use of cord blood, for new and/or additional research related to stem cell transplantation.
Course Director:
Dr. Mounzer E. Agha, MD
Clinical Director, Stem Cell Transplant Program
Director, Bone Marrow Transplantation Fellowship Program
Clinical Associate Professor of Medicine
University of Pittsburgh School of Medicine
CME Accreditation:
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded 0.6 continuing education units (CEU’s) which are equal to 6.25 contact hours.
